Posted by Michael Wonder on 27 Feb 2024
Etrasimod arginine for the treatment of patients with moderate to severe active ulcerative colitis
27 February 2024 - NICE has published final evidence-based recommendations on the use of etrasimod arginine (Velsipity) for the treatment of patients with moderate to severe active ulcerative colitis.
Etrasimod arginine is recommended as an option for the treatment of patients aged 16 years and over with moderate to severe active ulcerative colitis when conventional or biological treatments cannot be tolerated or the condition has not responded well enough, or lost response to treatment.
